Cat. #162325
Glioblastoma WHO IV spheroid cell line, NCH601
Cat. #: 162325
Organism: Human
Tissue: Brain
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Christel Herold-Mende
Institute: Heidelberg University
Primary Citation: Campos et al. 2014. J Pathol. 234(1):23-33. PMID: 24756862.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Glioblastoma WHO IV spheroid cell line, NCH601
- Cancer: Brain
- Organism: Human
- Tissue: Brain
- Growth properties: Mixed - adherent and suspension
- Description: Glioblastoma WHO IV spheroid cell line, NCH601
- Biosafety level: 2
Handling
- Growth medium: DMEM/F12 supplemented with 20% BIT supplement (Provitro), 2mM L-Glutamine, 30 U/ ml Pen-Strep, 1U/ml Heparin, 20 ng/ml bFGF, and 20ng/ml EGF
- Temperature: 37°C
- Atmosphere: 5% CO2
References
- Remy et al. 2022. Cancers. 14(2):339. PMID: 35053502.
- Cano-Galiano et al. 2021. Neurooncol Advances. 3(1). PMID: 34250481.
- Schuster et al. 2020. Nat Commun. 11(1):6366. PMID: 33311477.
- Golebiewska et al. 2020. Acta Neuropathol. 140(6):919-949. PMID: 33009951.
- Fritah et al. 2020. Cancers. 12(9):2583. PMID: 32927769.
- Biedermann et al. 2019. Cancers. 11(12):2028. PMID: 31888244.
- Rusu et al. 2019. Cell Stem Cell. 25(2):241-257. PMID: 31303549.
- Trong et al., 2018. Int J Mol Sci. 19(10):2903. PMID: 30257451.
- Schulze et al. 2018. BMC Cancer. 18(1):524. PMID: 29724193.
- Hoja et al. 2016. Oncotarget. 7(39):62989-63002. PMID: 27556305.
- Chiblak et al. 2016. Int J Radiat Oncol Biol Phys. 95(1):112-119. PMID: 26254681.
- Bougnaud et al. 2016. Oncotarget. 7(22):31955-31971. PMID: 27049916.
- Dokic et al. 2012. Glia. 60(11):1785-1800. PMID: 22951908.
- Campos et al. 2014. J Pathol. 234(1):23-33. PMID: 24756862.
